This image shows that the 90th ATA annual meeting will be virtual and held on September 30 to October 3 2021.

Schedule at a Glance - EDT


Session times are listed in Eastern Daylight Time

To view the poster presenters and abstract sessions, please click here

Thursday, September 30, 2021 – EDT

9:00 am – 6:00 pm Poster Viewing Open 9:00 – 11:00 am Ridgway Conference 9:00 – 6:00 pm Poster Viewing Open












2:00 – 3:00 pm

Highlighted Oral Abstracts




































10:00 – 10:50 am Early Riser
11:00 am – 12:15 pm Plenary: Year in Thyroidology

•Catherine Dinauer, MD and Christine Spitzweg, MD, Co-Chairs
•Antonio Di Cristofano, PhD, “Basic Science Review”
•Megan Haymart, MD, “Clinical Science Review”
•Ralph Tufano, MD, “Surgical Review”

12:15 – 1:00 pm Break & Poster Review
1:00 – 2:00 pm Plenary: Ingbar & Galton Award Lectures

•Matthew D. Ringel, MD – Sidney H. Ingbar Distinguished Lectureship
•Sheue-yann Cheng, Ph.D. Valerie Anne Galton Distinguished Lectureship

2:00 – 4:00 pm
ediatric Thyroid ForumAndrew Bauer, MD, Pallavi Iyer, MD and Jonathan Wasserman, MD, ModeratorsTargeted Medical Therapies for Differentiated Thyroid Cancer in Children
•Theodore Laetsch, MDMedical Therapies for Medullary Thyroid Cancer in Children
•John Glod, MD, PhDUpdate on Thyroid Hormone Replacement in Children: Is There a Role for T3 or Newer Formulations?
•Gary Francis, MD, PhD
Highlighted Posters• The Molecular Landscape of Pediatric Thyroid Nodules and The Utility of the ThyroSeq v3 Multigene Genomic Classifier in Children – Jean-Nicolas Gallant, MD, PhD• Comparing Deep Learning to Radiologists’ Overall Impression in the Assessment of Pediatric and Young Adult Thyroid Nodules – Laura Page, MD
Surgical Symposium

Small Primary Cancers:  Observe, Ablate, or Operate?
•Mark Zafereo, MD
•Yasuhiro Ito, MD, PhD
•Jennifer Kuo, MD
•Jonathon Russell, MD

Management of Recurrent Thyroid Cancer
•Elizabeth Grubbs, MD
•Laura Boucai, MD
•Linwah Yip, MD
•David Shonka, MD






















Thyroid Eye Disease Symposium

•Henry Burch, MD and Petros Perros, Co-Chairs

What have we learned about the underlying molecular mechanisms in recent years?
•Susanne Neumann, MD

Novel medical therapies for TED – what and when?
•Marius Stan, MD and Mario Salvi, MD

Is surgical management of TED changing with available medical options?
•Suzanne Freitag, MD

Initial data from ATA/ETA member survey on TED
•JP Brito, MD

Overview of the ATA/ETA Statement on Management of TED
•Henry Burch, MD and Petros Perros, MD









Highlights of ATA Research Grants

Joanna Klubo-Gwiezdzinska, MD, PhD and Carmelo Nucera, MD, PhD, Co-Chairs

Glutamine Metabolism is a new Therapeutic Target in Thyroid Cancer
•Myriem Boufraqech, PhD

Structure Determination of Mammalian Thyroglobulin by cryoEM
•Oliver Clarke, PhD

Novel Targeted Immunotherapies for Autoimmune Thyroid Diseases
•Cheuk Wun Li, PhD

























4:00 – 5:00 pm Meet the ATA Leadership Networking Event
4:00 – 5:00 pm Highlighted Poster Presentation Sessions

Friday, October 1, 2021 – EDT

9:00 am Poster Viewing Open 9:00 – 6:00 pm Poster Viewing Open
10:00 – 10:50 am Early Riser
11:00 am – 12:00 pm Plenary: Braverman & Van Meter Award Lectures

• Kenneth D. Burman, MD – Lewis E. Braverman Distinguished Lectureship
• Van Meter Award Lecturer to be announced during the plenary session

12:00 – 1:00 pm
Basic Science Oral Abstracts



Clinical Science Oral Abstracts














Meet the Professor: Molecular Testing in the Era of Personalized Thyroid Cancer Therapy and its Challenges

•Ashish Chintakuntlawar, MD, Moderator

Clinical Perspectives on Molecular Testing and Personalized Thyroid Cancer Therapy
•Mimi Hu, MD

Pathology Perspectives on Molecular Testing and Personalized Thyroid Cancer Therapy
•Thomas Giordano, MD, PhD

Meet the Professor: What’s New in the Pathogenesis of Thyroid Autoimmunity

• Leonidas Duntas, MD, Moderator

Basic/Translational Update of Autoimmune Thyroiditis
• Francesca Coscia, PhD

Clinical Update in Thyroid Autoimmunity
• Giuseppe Barbesino, MD




1:00 – 2:00 pm Sponsored Symposium Poster Viewing
2:00 – 3:00 pm Thyroid Cancer Through the Ages

• Whitney Goldner, MD and Andy Bauer, MD Co-Chairs

Perspectives From a Pediatric and Adult Endocrinologist: Advances and Gaps in Care Across the Age Spectrum
• Steve Waguespack, MD

Challenges and Considerations in the Care of Adolescent and Young Adult (AYA) with Thyroid Cancer
• Melanie Goldfarb, MD

Practical Considerations on Managing Thyroid Cancer in Older Adults
• Maria Papaleontiou, MD


Chromatin Modification by
• Anthony Hollenberg, MD and Sheue-yann Cheng, PhD Co-ChairsT3-dependent Epigenetic Coordination by TR
• Frances Carr, PhDHistone and DNA Modifications in Amphibians
• Yun-Bo Shi, PhDThyroid Hormone Induction of DNA Demethylation in Developing Brain
• Robert Denver, PhD
COVID19 and the Thyroid

• Rossella Elisei, MD and Peter Kopp, MD, Co-chairs

The Spectrum of Thyroid Function Abnormalities in COVID-19 Patients
• Laura Fugazzola, MD

Treatment of SARS with L-T3
• David Ingbar, MD

Analysis of Risk, Disparity and Outcomes in COVID-19 Patients with Thyroid Cancer
• Melissa Lechner, MD


Meet the Professor: Treatment of Hyperthyroidism: Past and Present

• Tracy Tylee, MD, Moderator

Long Term ATD – Is it a Better Way?
• Fereidoun Azizi, MD

Shifts in Treatment Preferences – Where we were, Where we are, and Where we’re going
• Doug Ross, MD





3:00 – 4:00 pm Women in Thyroidology Program & Networking
• Regina Castro, MD, WIT PresidentFeatured Speakers
• Julie Ann Sosa, MD
• Nancy Carrasco, MD
Highlighted Poster Presentations







4:00 – 6:00 pm Poster Viewing Open

Saturday, October 2, 2021 – EDT

9:00 am Poster Viewing Open 9:00 – 6:00 pm Poster Viewing Open
10:00 – 10:50 am Early Riser
11:00 am – 12:00 pm Plenary: Celebrating 25 Years of Cloning of the Sodium Iodide Symporter and 80 Years of Radioiodine Therapy

• John Morris, MD and Sissy Jhiang, PhD Co-Chairs
• Gregory A. Brent, MD, “NIS- The basis of 80 years of radioiodine therapy in benign and malignant disease”
• Nancy Carrasco, MD, “NIS – The journey since its cloning 25 years ago”

12:00 – 1:00 pm Basic Science Oral Abstracts








Clinical Oral Abstracts








Meet the Professor: Global Trends in Thyroid Cancer Epidemiology

•Cari Kitahara, PhD, Moderator

Impact of Overdiagnosis on International Patterns in Thyroid Cancer Incidence and Mortality
•Salvatore Vaccarella, PhD

Is There Evidence of True Increase in Incidence?
•Susan Jordan, PhD

Meet the Professor: Thyroid Challenges in Pregnancy

Kris Poppe, MD, Moderator

Issues in the Pregnant or Lactating Patient with Thyroid Cancer
Angela Leung, MD

Preconception Counselling and Care for Pregnant Women with Autoimmune Thyroid Disease
Kristien Boelaert, MD


1:00 – 2:00 pm Sponsored Symposium Poster Viewing
2:00 – 3:00 pm Treatments for Hypothyroidism-A Changing Paradigm

• Anne Cappola, MD and Laszlo Hegedus, MD, DMSc Co-Chairs

How to Use LT3 + LT4 today
• Jacqueline Jonklaas, MD, PhD

Clinical Trials Underway
• Colin Dayan, MA,FRCP,PhD

New Formulations of Liothyronine
• Antonio Bianco, MD, PhD




Defects in Deiodination Pathways with Clinical Significance

• Monica Dentice, PhD, Chair

Loss-of-Function Mutations of DIO1
• Alexandra Dumitrescu, MD, PhD

Loss-of-Function Mutations of DIO2
• Jose Moreno, MD, PhD

Syndromes of DIO3 Reactivation
• Dominico Salvatore, MD




Celebrating 10 years of FDA Approved Novel Treatments for Thyroid Cancer

•Steven Sherman, MD and Lori Wirth, MD Co-Chairs

Targeted Therapies in DTC and MTC: Where Have we Started and What Have we Achieved
•Manisha Shah, MD

Update in Management of Anaplastic Thyroid Cancer: 2021 ATA Guidelines
•Keith Bible, MD

Current and Upcoming Clinical Trials in Thyroid Cancer
•Maria Cabanillas, MD

Meet the Professor: Management of Thyrotoxic Conditions

• Cord Sturgeon, MD, MS, FACS, Moderator

Consideration for Surgery vs RAI Referral
• Brian Kim, MD

Preop Management of the Thyrotoxic Patient, Operative Considerations and Challenges, and Postop Challenges
• Susan Pitt, MD





3:00 – 4:00 pm ATA Awards Celebration & Business Meeting
4:00 – 6:00 pm Poster Viewing Open


4:00 – 5:00 pm – Highlighted Poster Presentations

Sunday, October 3, 2021 – EDT

9:00 am Poster Viewing Open 9:00 – 3:00 pm Poster Viewing Open
10:00 – 10:50 am Early Riser
11:00 am – 12:00 pm Plenary-Arthur Bauman Clinical Symposium Disparities in Thyroid Care: Bridging Gaps

• M. Regina Castro, MD and Ernest Asamoah, MD, Co-Chairs
• Emad Kandil, MD, “Disparities in Surgical Management of Thyroid Disease”
• Julie Ann Sosa, MD, “Disparities in Differentiated Thyroid Cancer Care”
• Donald S. A. McLeod, MBBS, MPH, PhD, “Disparities in Management of Graves’ Disease”

12:00 – 1:00 pm Basic Science Oral Abstract Session Clinical Science Oral Abstract Session Meet the Professor: Call 911: Thyroid Emergencies

• Andrew Gianoukakis, MD, Moderator

Thyroid Storm: Myths and Facts
• Takashi Akamizu, MD

Thyroid lymphoma: a diagnosis to consider in the rapidly enlarging thyroid mass
• Anu Sharma, MD

Meet the Professor: Disorders of Thyroid Function with a Genetic Basis
• Roy Weiss, MD, PhD, Moderator
Update on Syndromes of Resistance to Thyroid Hormone
• Carla Moran, MB, PhD
Diagnosis and Treatment of MCT8 Deficiency/Allan-Herndon-Dudley Syndrome
• W. Edward Visser, MD, PhD
1:00 – 2:00 pm Sponsored Symposium Poster Viewing
2:00 – 3:00 pm NIS & Radioiodine: What’s in the Pipeline?

• Pilar Santisteban, PhD and Christine Spitzweig, MD Co-Chairs

Pathophysiology of Radioiodine-Refractory DTC
• James Fagin, MD

Update on Redifferentiation Trials in Radioiodine-Refractory DTC
• Sophie Leboulleux, MD

New Insights into Regulation of NIS Expression and Function
• Chris McCabe, PhD




Immune Checkpoint Inhibitor Therapy for Thyroid Cancer: Current State & Future Directions

• Bhavana Konda, MD, MPH and Mabel Ryder, MD, Co-Chairs

Management of Endocrine Side Effects of Immunotherapy
• Anupam Kotwal, MD

Pembrolizumab and Lenvatinib – A Powerful Duo in Differentiated and Undifferentiated Thyroid Cancer
• Bryan Haugen, MD

Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy for the Development of Rational Combination Therapies
• Padmanee Sharma, MD, PhD


Clark T. Sawin Historical Vignette: Edwin B. Astwood and the Development of the Antithyroid Drugs
• David S. Cooper, MD
• Jerome M. Hershman, MD

Meet the Professor: Did my patient get appropriate nodal dissection?
•David Steward, MD
•Michael Yeh, MD
3:00 – 3:15 pm Closing Remarks: New ATA President Peter Kopp